Objective: To study of the effect and mechanism of modified Erchentang on Clara cell protein (CC16)

pulmonary surfactant associated protein-D (SP-D)

histone acetyl transferase (HAT) and histone deacetylase (HDAC) in patients at acute aggravating stage of COPD. Method: Totally 200 cases at acute exacerbation period of COPD (AECOPD) were randomly divided into modified Erchentang group and placebo-controlled group

with 100 cases in each group. In addition to western drugs

modified Erchentang was also used in the modified Erchentang group

and placebo was also used in control group for 14 days. Their pulmonary function was detected

and euzyme-linked immunosorbent assay was used to determine the levels of C-reactive protein (CRP)

interleukin-17 (IL-17)

CC16

SP-D

HDAC1 and HAD2 in plasma and exhaled breath condensate of all groups. The activities of HAT and HDAC were determinate by enzyme-linked immune fluorescence. Result: The activity of HDAC2 was higher significantly

but the levels of CRP

IL-17

CC16 and SP-D (P<0.05

P<0.01) in plasma and exhaled breath condensate

and the activity of HAT were significantly decreased in treatment group with modified Erchentang

compared with those in control group. Conclusion: Modified Erchentang may have an effect on COPD by adjusting the HAT/HDAC

reducing levels of CRP

IL-17

CC16 and SP-D

preventing inflammation progress and improving the structure and function of respiratory system and lungs.